Statins as a component of lipid-lowering therapy

Cover Page

Cite item

Full Text

Abstract

Statins are the main class of drugs that are used to treat patients with hyperlipidemia and atherosclerosis. Over the past decades, dozens of randomized clinical trials with this group of drugs have been conducted. Their results showed a significant reduction in cardiovascular and overall mortality, regardless of gender, age, baseline cholesterol levels. Currently, 6 drugs of this class are registered in the Russian Federation: Atorvastatin, Lovastatin, Simvastatin, Pravastatin, Rosuvastatin and Fluvastatin.

About the authors

Andrey I. Danilov

Smolensk State Medical University

Author for correspondence.
Email: dr.DanAndr@yandex.ru

PhD, Assistant, Department of Clinical Pharmacology

Russian Federation, Smolensk

Sergey N. Kozlov

Smolensk State Medical University

Email: snk@antibiotic.ru

Dr Med Sci, Professor, Head, Department of Clinical Pharmacology

Russian Federation, Smolensk

Andrey V. Evseev

Smolensk State Medical University

Email: hypoxia@yandex.ru

Dr Med Sci, Professor, Head, Department of Physiology, Research Center

Russian Federation, Smolensk

References

  1. Данилов А.И., Литвинов А.В., Козлов С.Н., и др. Многоликая ацетилсалициловая кислота (к 120-летию создания антиагреганта) // Клиническая фармакология и терапия. – 2018. – Т. 27. – № 1. – С. 79–82. [Danilov AI, Litvinov AV, Kozlov SN, et al. Many faces of acetylsalicylic acid (on the 120th anniversary of the discovery of the antiplatelet). Klinicheskaia farmakologiia i terapiia. 2018;27(1):79-82. (In Russ.)]
  2. Данилов А.И., Козлов С.Н., Евсеев А.В. Антагонисты альдостерона в кардиологической практике // Обзоры по клинической фармакологии и лекарственной терапии. – 2019. – Т. 17. – № 2. – С. 73–77. [Danilov AI, Kozlov SN, Evseev AV. Aldosterone antagonists in cardiologicy practice. Reviews on Clinical Pharmacology and Drug Therapy. 2019;17(2):73-77. (In Russ.)]. https://doi.org/ 10.7816/RCF17273-77.
  3. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis. 1980;35(3):259-266. https://doi.org/ 10.1016/0021-9150(80)90124-0.
  4. Gofman JW, Lindgren F, Elliott H, et al. The Role of Lipids and Lipoproteins in Atherosclerosis. Science. 1950;111(2877):166-186. https://doi.org/ 10.1126/science.111.2877.166.
  5. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976;29(12): 1346-1348. https://doi.org/ 10.7164/antibiotics.29.1346.
  6. Кухарчук В.В., Коновалов А.А., Сусеков А.В., и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр // Атеросклероз. – 2012. – Т. 8. – № 2. – С. 61–93. [Kukharchuk VV, Konovalov AA, Susekov AV, et al. Diagnostika i korrektsiya narusheniy lipidnogo obmena s tsel’yu profilaktiki i lecheniya ateroskleroza. Rossiyskie rekomendatsii. V peresmotr. Ateroskleroz. 2012;8(2):61-93. (In Russ.)]
  7. Арутюнов А.Г., Арутюнов Г.П. Коррекция статинами сердечно-сосудистого риска. Проблемы и нерешенные вопросы на современном этапе // Сердце: журнал для практикующих врачей. – 2015. – Т. 14. – № 4. – С. 193–212. [Arutyunov AG, Arutyunov GP. Correction of cardiovascular risk with statins. Challenges and unsolved issues at the current stage. Serdtse. 2015;14(4):193-212. (In Russ.)]. https://doi.org/ 10.18087/rhj.2015.4.2093.
  8. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA. 1982; 248(12): 1465-1477.
  9. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389. https://doi.org/ 10.1016/S0140-6736(94)90566-5.
  10. Boekholdt SM, Hovingh GK, Mora S, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64(5):485-494. https://doi.org/ 10.1016/j.jacc.2014.02.615.
  11. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278. https://doi.org/ 10.1016/s0140-6736(05)67394-1.

Copyright (c) 2020 Danilov A.I., Kozlov S.N., Evseev A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).